Psycholytic dosing or 'microdosing' of Amanita muscaria (red fly agaric) mushrooms—A retrospective case study
PsyArXiv November 7, 2023 preprint DOI: 10.31234/osf.io/dve46
Summary
AI-generated from the abstractA woman in her early thirties with depression, anxiety, and sleep disorders from childhood trauma microdosed Amanita muscaria mushrooms over 3.5 months following a dream's advice. Using an intuition-based, gradually declining dosing scheme, her symptoms significantly decreased without adverse effects. Blood tests showed no abnormalities and a slight improvement in liver function, possibly from reduced sugar addiction and muscimol's hepatoprotective effect. These findings align with existing literature on psycholytic dosing.
Study at a glance
| Characteristics | Case study Case report |
|---|---|
| Sample size | 1 |
| Population | A woman in her early thirties with depression, anxiety, and sleep disorders from childhood trauma |
| Duration | 3.5-month period |
| Citations | 2 |
| Key finding | Microdosing Amanita muscaria led to significant symptom reduction in a woman with complex trauma-related depression, anxiety, and sleep disorders. |
Abstract
Following advice received in a dream, a woman in her early thirties, suffering from depression, anxiety, and sleep disorders caused by complex trauma in her childhood, experimented with 'microdosing' or psycholytic dosing of Amanita muscaria (fly agaric) mushrooms. During a 3.5-month period with an intuition-based, gradually declining dosing scheme, her symptoms significantly decreased. No adverse effects were observed. Hematological tests revealed no abnormalities but indicated a slight improvement in liver function, possibly due to the remission of addictive behavioral patterns related to sugar consumption and the hepatoprotective effect of muscimol. All findings were consistent with the current literature on this method.